Evidence map›Paper›PMID 32164579›Full record

ArticleBMC cancer2020

A phase II open label, randomised study of ipilimumab with temozolomide versus temozolomide alone after surgery and chemoradiotherapy in patients with recently diagnosed glioblastoma: the Ipi-Glio trial protocol.

Nicholas F Brown, Stasya M Ng, Claire Brooks, Tim Coutts, Jane Holmes, Corran Roberts, Leena Elhussein, Peter Hoskin, Tim Maughan, Sarah Blagden and 1 more

Open access · goldAbstract readClinical Trial ProtocolComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed, 1 pooled it
3.0field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 1 synthesis or guideline pooled it, 50 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. Review
  20. Treatment advances in high-grade gliomas.Frontiers in oncology · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Nicholas F BrownDepartment of Oncology, University College London Hospitals, 250 Euston Road, London, NW1 2PQ, UK.
Stasya M NgOncology Clinical Trials Office (OCTO), Department of Oncology, The University of Oxford, Old Road Campus Research Building, Oxford, OX3 7DQ, UK.
Claire BrooksOncology Clinical Trials Office (OCTO), Department of Oncology, The University of Oxford, Old Road Campus Research Building, Oxford, OX3 7DQ, UK.
Tim CouttsOncology Clinical Trials Office (OCTO), Department of Oncology, The University of Oxford, Old Road Campus Research Building, Oxford, OX3 7DQ, UK.
Jane HolmesCentre for Statistics in Medicine (CSM), University of Oxford, Botnar Research Centre, Windmill Road, Oxford, OX3 7LD, UK.
Corran RobertsCentre for Statistics in Medicine (CSM), University of Oxford, Botnar Research Centre, Windmill Road, Oxford, OX3 7LD, UK.
Leena ElhusseinCentre for Statistics in Medicine (CSM), University of Oxford, Botnar Research Centre, Windmill Road, Oxford, OX3 7LD, UK.
Peter HoskinMount Vernon Cancer Centre, Rickmansworth Road, Northwood, HA6 2RN, UK.
Tim MaughanOxford Institute for Radiation Oncology, University of Oxford, Old Road Campus Research Building, Roosevelt Drive, Oxford, OX3 7DQ, UK.
Sarah BlagdenDepartment of Oncology, University of Oxford, Old Road Campus Research Building, Oxford, OX3 7DQ, UK.
Paul MulhollandDepartment of Oncology, University College London Hospitals, 250 Euston Road, London, NW1 2PQ, UK. paul.mulholland@nhs.net.ORCID http://orcid.org/0000-0002-7926-824X
University of Oxford · GBMount Vernon Cancer Centre · GBUniversity College Hospital · GBUniversity College London Hospitals NHS Foundation Trust · GB

Funding

Cancer Research UK 16895Cancer Research UK 27294
6 · The paper itself

Abstract

backgroundMedian survival for patients with glioblastoma is less than a year. Standard treatment consists of surgical debulking if feasible followed by temozolomide chemo-radiotherapy. The immune checkpoint inhibitor ipilimumab targets cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and has shown clinical efficacy in preclinical models of glioblastoma. The aim of this study is to explore the addition of ipilimumab to standard therapy in patients with glioblastoma. METHODS/

designIpi-Glio is a phase II, open label, randomised study of ipilimumab with temozolomide (Arm A) versus temozolomide alone (Arm B) after surgery and chemoradiotherapy in patients with recently diagnosed glioblastoma. Planned accrual is 120 patients (Arm A: 80, Arm B: 40). Endpoints include overall survival, 18-month survival, 5-year survival, and adverse events. The trial is currently recruiting in seven centres in the United Kingdom.

trial registrationISRCTN84434175. Registered 12 November 2018.

Indexed as

Brain NeoplasmsGlioblastomaIpilimumabTemozolomideAdultAgedChemoradiotherapyClinical Trials, Phase II as TopicCytoreduction Surgical ProceduresFemaleHumansMaleMiddle AgedMulticenter Studies as TopicRandomized Controlled Trials as TopicSurvival AnalysisIpilimumabTemozolomideGlioblastomaGliomaIpilimumabTemozolomide

Identifiers

PMID32164579
PMCPMC7068928
OpenAlexW3011587695

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.